Greenwich LifeSciences Initiates European Clinical Sites with GEICAM

Greenwich LifeSciences, a biopharmaceutical company, has announced the commencement of clinical sites in Europe for its Phase III FLAMINGO-01 trial. The trial is assessing GLSI-100, an immunotherapy intended to prevent the recurrence of breast cancer. The collaboration with GEICAM, Spain's largest academic breast cancer research network, involves 38 hospitals that have consented to take part in the study. GEICAM, established in 1995, is a non-profit entity that has facilitated over 140 studies impacting thousands of individuals and is composed of a vast team of experts across numerous hospitals.

Breast cancer remains the most frequently diagnosed cancer among women in Spain, with a significant number of new cases reported annually. The FLAMINGO-01 Steering Committee member, Professor Miguel Martin, highlights the progress made in treating HER2+ tumors, which were once associated with poor prognoses. Despite advancements in anti-HER2 therapies, there is still a need for further improvement, and the vaccine under investigation in the FLAMINGO-01 study is seen as a promising step towards reducing relapses without exacerbating treatment side effects.

The FLAMINGO-01 study is designed to include patients with high-risk HER2+ breast cancer who have completed standard treatments. The trial will examine the potential benefits of a vaccine based on the GP2 peptide, which, when combined with an adjuvant, is believed to trigger a specific antitumor immune response in certain patients. The trial's innovative approach lies in its focus on anti-HER2 vaccines within the context of a randomized phase 3 study, with previous studies indicating promising results and an acceptable safety profile.

Dr. Eva Carrasco, GEICAM's Scientific Director and CEO, underscores the significance of partnerships between academia and the pharmaceutical industry, as well as international collaboration, in advancing breast cancer research and drug development. The trial aims to compare the vaccine's efficacy against a control group in an adjuvant setting, marking a novel therapeutic strategy in the field of breast cancer treatment.

Greenwich LifeSciences' CEO, Snehal Patel, expresses gratitude for the collaboration with GEICAM and looks forward to working closely with them as the trial progresses. The clinical trial's details, including the list of participating sites, can be found on clinicaltrials.gov, providing a comprehensive resource for interested parties.

The FLAMINGO-01 trial is a crucial step in the ongoing battle against breast cancer, particularly for patients with HER2+ tumors. With the support of GEICAM and the expertise of its team, the study represents a significant endeavor to enhance the prevention of breast cancer recurrences and improve patient outcomes.